OrbitonOpen research workspace →
Baxter International Inc. logo

Baxter International Inc.

NYSE:BAXLive AI agent

Baxter is a global healthcare company dedicated to transforming patient care through innovative medical devices, connected solutions, and injectable medicines.

Investor website: https://baxter.com/

About

Baxter is a global healthcare company dedicated to transforming patient care through innovative medical devices, connected solutions, and injectable medicines. With a mission to save and sustain lives, Baxter collaborates with healthcare professionals to enhance patient care and improve clinical outcomes worldwide.

Verified company data

Shares outstanding
515
Fully diluted shares
515
Projects
["Baxter Announces Acquisition of PerClot Polysaccharide Hemostatic System to Expand Advanced Surgery Portfolio\n\nPublished Date: 29 Jul 2021\n\nPublished Location:\n**DEERFIELD, Ill.**\n\n- _**Marks Baxter’s entry into the attractive global hemostatic powder segment, broadening its portfolio offering to include a wider range of active and passive solutions**_\n\nBaxter International Inc. (NYSE:BAX), a leading global medical products company, announced its Baxter Healthcare Corporation subsidiary has completed the acquisition of certain assets related to **PerClot** **Polysaccharide Hemostatic System** from CryoLife, Inc (NYSE:CRY) for up to $60.8 million, including $25 million paid upfront. The remainder will be paid out upon achievement of certain select milestones. The transaction reinforces Baxter’s strategy of acquiring products and technologies that both complement and augment the company’s leading portfolio across the hospital, including in the operating room. **PerClot** has a global commercial presence with sales in more than 35 countries worldwide. It is not currently cleared for sale in the United States.\n\n“The addition of **PerClot** further enhances our ability to optimize patient care by addressing a broad range of intraoperative bleeding with both active and passive hemostatic solutions, helping surgeons to use the right product for the right bleed,” said Wil Boren, president of Baxter’s Advanced Surgery business. “ **PerClot** launches Baxter into the attractive hemostatic powder segment, while expanding our surgical offerings and complementing our recent acquisition of **Seprafilm** Adhesion Barrier.”\n\nAddressing intraoperative bleeding is important in preventing blood transfusions and major complications for patients, as well as reducing the total cost of care. A blood management strategy that includes effective hemostasis is especially critical in today’s environment, given current worldwide shortages of blood donations and products due to the ongoing COVID-19 pandemic. A [recent retrospective analysis](https://www.baxter.com/news-insights/baxter-supports-analysis-demonstrating-clinical-economic-benefits-effective-intraoperative-blood-management-for-surgical-patients \"Baxter Supports Analysis Demonstrating Clinical and Economic Benefits of Effective Intraoperative Blood Management for Surgical Patients\") found that implementing a framework that incorporates patient factors and a bleeding severity tool, such as Baxter’s Validated Intraoperative Bleeding Scale ( **VIBe SCALE**), can support optimal hemostatic product selection.1\n\nA polysaccharide hemostatic powder can be used as an adjunctive hemostat to facilitate control of bleeding from capillary, venous or arteriolar vessels to address low-grade intraoperative bleeding.2 **PerClot** is composed of plant starch that is modified to create an adhesive hemostatic powder. It is used as an adjunctive hemostatic device to control bleeding during multiple open and laparoscopic surgical procedures, including gynecologic, general, cardiovascular and urology. **PerClot** rapidly absorbs water from blood to produce a gelled matrix that adheres to and forms a mechanical barrier with the bleeding tissue.\n\nCryoLife recently completed a [multicenter, randomized controlled clinical trial](https://www.clinicaltrials.gov/ct2/show/NCT02359994?term=Perclot&draw=2) of more than 300 patients intended to support an application for U.S. Food and Drug Administration (FDA) clearance. The trial evaluated the safety and efficacy of **PerClot** in achieving intraoperative hemostasis compared to the control (a similar marketed hemostatic powder).\n\n### **Important Safety Information for PerClot in the European Union (EU)**\n\n**Indications: PerClot** Polysaccharide Hemostatic System (PHS) is indicated for use in surgical procedures (except neurological and ophthalmic) or injuries as an adjunct hemostat when control of bleeding from capillary, venous, or arteriolar vessels by pressure, ligature, and other conventional means is either ineffective or impractical.\n\n**Contraindications:** Do not apply **PerClot** PHS into blood vessels as potential for embolization and death may exist. **PerClot** PHS is contraindicated in patients who are sensitive to starch or starch-derived materials.\n\n**Warnings: PerClot** PHS is not intended as a substitute for good surgical practice, and in particular, the proper use of conventional procedures (such as ligature) for hemostasis.\n\n**PerClot** PHS is not recommended when an infection is suspected. **PerClot** PHS should be used with caution in contaminated areas. If signs of an infection develop in the site where **PerClot** PHS has been used, surgery may be necessary to allow adequate drainage.\n\nCombined use of **PerClot** PHS with other topical hemostatic agents has not been studied in controlled clinical trials.\n\nRemove excess absorbable modified polymer ( **AMP)** particles once hemostasis is achieved. This removal of excess particles is particularly important in and around the spinal cord, areas of bone confine, the optic nerve/chiasm, and foramina of bone because unsaturated particles may swell and compress the surrounding tissues.\n\n**PerClot** PHS should not be mixed with methylmethacrylate or other acrylic adhesives as it may reduce the adhesive strength and compromise the attachment of prosthetic devices to bone tissue. Excess particles should be fully removed from bony surfaces by irrigation prior to the use of adhesives.\n\nSafety and effectiveness of **PerClot** PHS have not been clinically evaluated in children and pregnant women.\n\nWhen **PerClot** PHS is used in the nasal cavity and laryngopharyngeal, **PerClot** PHS should be used with caution to avoid the dry particles being drawn into the trachea or bronchi, which may form a gel that blocks the trachea and bronchi.\n\n**PerClot** PHS is a single use product. Do not use **PerClot** PHS in more than a single surgical procedure.\n\n**PerClot** PHS should not be used for controlling post-partum bleeding or menorrhagia.\n\nSafety and effectiveness in neurological and ophthalmic procedures has not been studied in controlled clinical trials."]
Leadership
William A. Ampofo II (Senior Vice President, Parts & Distribution and Supply Chain, Boeing Global Services), Jeffrey (Jay) A. Craig (Former Chair and Chief Executive Officer, Meritor Corporation), Andrew Hider (President and Chief Executive Officer), Michael R. McDonnell (Former Executive Vice President and Chief Financial Officer, Biogen Inc.), Patricia B. Morrison (Former Executive Vice President, Customer Support Services and Chief Information Officer, Cardinal Health Inc.), Nancy M. Schlichting (Former President and Chief Executive Officer, Henry Ford Health System), Brent Shafer (Chair of the Board and Former Chair and Chief Executive Officer, Cerner Corporation), Amy A. Wendell (Former Senior Vice President, Strategy and Business Development and Licensing, Covidien), David S. Wilkes, M.D. (Dean Emeritus of the University of Virginia School of Medicine), James Borzi (Executive Vice President, Chief Supply Chain Officer), Cynthia (Cindy) Carlisle (Executive Vice President and Chief Human Resources Officer), Stacey Eisen (Senior Vice President, Chief Communications Officer and Corporate Marketing, and President, Baxter Foundation), Julie Foster (President, Front Line Care), Adriana Guiry (Senior Vice President, Baxter Growth & Performance System), Scott Kaplan (Senior Vice President, Quality, Regulatory & Patient Safety), Piero Novello (Senior Vice President and President, International), Charles (Rusty) Patel (Senior Vice President and Chief Information Officer), David S. Rosenbloom (Executive Vice President and General Counsel), Cecilia Soriano (Group President, Infusion Therapies and Platforms), James Teaff (President, Care & Connectivity Solutions), Steve Wallace (President, Advanced Surgery & Commercial Excellence)

Verified data last updated:

Recent filings